Targeting erlotinib-resistant lung cancer with rational combination treatments

$278,458P50FY2008CANIH

Dana-Farber Cancer Inst, Boston MA

Investigators

Jeffrey E Settlemancontact

Linked publications & trials

Paper 39176091 Paper 35693292 Paper 33651148 Paper 33472890 Paper 33400994 Paper 32676321 Paper 32493705 Paper 32393777 Paper 32072637 Paper 31713888 Paper 31618441 Paper 31216465 Paper 30989732 Paper 30700444 Paper 30683880 Paper 30650190 Paper 30613479 Paper 30444685 Paper 30259978 Paper 30254314 Paper 30185536 Paper 30167080 Paper 30104567 Paper 29981437 Paper 29859855 Paper 29713584 Paper 29413057 Paper 28611010 Paper 28440542 Paper 28400551 Paper 28346824 Paper 28304396 Paper 28285689 Paper 28202526 Paper 28150878 Paper 28120396 Paper 28111612 Paper 28104537 Paper 27805284 Paper 27713484 Paper 27488898 Paper 27488534 Paper 27413714 Paper 27371729 Paper 27283860 Paper 27197281 Paper 27080216 Paper 27055085 Paper 26964772 Paper 26943236 Paper 26905588 Paper 26883990 Paper 26870794 Paper 26845194 Paper 26833127 Paper 26798593 Paper 26791794 Paper 26776293 Paper 26757251 Paper 26724471 Paper 26720421 Paper 26620497 Paper 26601054 Paper 26590902 Paper 26515464 Paper 26503035 Paper 26384272 Paper 26363033 Paper 26199339 Paper 26039412 Paper 26036643 Paper 26001533 Paper 25922291 Paper 25876525 Paper 25873736 Paper 25804397 Paper 25758528 Paper 25738220 Paper 25726730 Paper 25724526 Paper 25700797 Paper 25682925 Paper 25667133 Paper 25657573 Paper 25624436 Paper 25512530 Paper 25452685 Paper 25394791 Paper 25381453 Paper 25349422 Paper 25296354 Paper 25238247 Paper 25218177 Paper 25164010 Paper 25103824 Paper 25035393 Paper 24982195 Paper 24880342 Paper 24857677 Paper 24857124

View original record on NIH RePORTER →